Quantcast

Latest Alemtuzumab Stories

2014-07-28 13:28:02

University of Oxford Oxford University scientists have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation. The key results are reported in The Lancet and presented at the World Transplant Congress in San Francisco today. They will help doctors faced with a difficult transplant conundrum: the powerful combinations of...

2014-07-09 16:25:02

LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 https://www.reportbuyer.com/product/2225869/OpportunityAnalyzer-Chronic-Lymphocytic-Leukemia---Opportunity-Analysis-and-Forecasts-to-2018.html OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 SummaryChronic lymphocytic leukemia (CLL), the most common...

2014-06-23 12:29:04

AUSTIN, Texas, June 23, 2014 /PRNewswire/ -- XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's clinical trial team and manage the Company's international clinical operations. Mr. Gonzales joins XBiotech from INC Research where he managed large, global pivotal phase III trials. Mr. Gonzales has B.S. & M.S. degrees in chemistry and biology and also holds a M.B.A. Mr. Gonzales comes to...

2014-06-05 23:03:26

In-demand research report “Chronic Lymphocytic Leukaemia: KOL Insight” worked out by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB) June 05, 2014 Chronic lymphocytic leukaemia (CLL) is the most common type of the leukaemias. Nevertheless, until recently, it has been underserved in terms of effective therapeutic options. However, a revolution in targeted and personalized therapies is tremendously altering the treatment algorithm and also spurs the development of...

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-04-17 16:27:38

LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra(®) (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered...

2014-02-27 16:25:58

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM)(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a...

2014-02-27 08:29:40

MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM) (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first...

2014-02-27 08:26:12

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM)(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a...

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related